Market closedNon-fractional
Spero Therapeutics/SPRO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Spero Therapeutics
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Ticker
SPRO
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Cambridge, United States
Employees
46
Website
sperotherapeutics.com
SPRO Metrics
BasicAdvanced
$71M
Market cap
3.02
P/E ratio
$0.43
EPS
0.62
Beta
-
Dividend rate
Price and volume
Market cap
$71M
Beta
0.62
Financial strength
Current ratio
3.351
Quick ratio
3.264
Long term debt to equity
3.656
Total debt to equity
5.448
Management effectiveness
Return on assets (TTM)
12.06%
Return on equity (TTM)
29.06%
Valuation
Price to earnings (TTM)
3.023
Price to revenue (TTM)
0.625
Price to book
0.73
Price to tangible book (TTM)
0.73
Price to free cash flow (TTM)
-4.884
Growth
Revenue change (TTM)
107.40%
Earnings per share change (TTM)
-168.69%
3-year revenue growth
95.17%
3-year earnings per share growth
-47.51%
What the Analysts think about SPRO
Analyst Ratings
Majority rating from 4 analysts.
SPRO Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$9.2M
-87.48%
Net income
-$13M
-124.66%
Profit margin
-136.95%
-296.99%
SPRO Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.23
-$0.06
$0.96
-$0.24
-
Expected
-$0.34
-$0.03
-$0.10
-$0.04
-$0.38
Surprise
-33.01%
100.00%
-1,060.00%
453.85%
-
SPRO News
AllArticlesVideos
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·3 days ago
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·1 month ago
Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Spero Therapeutics stock?
Spero Therapeutics (SPRO) has a market cap of $71M as of July 06, 2024.
What is the P/E ratio for Spero Therapeutics stock?
The price to earnings (P/E) ratio for Spero Therapeutics (SPRO) stock is 3.02 as of July 06, 2024.
Does Spero Therapeutics stock pay dividends?
No, Spero Therapeutics (SPRO) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Spero Therapeutics dividend payment date?
Spero Therapeutics (SPRO) stock does not pay dividends to its shareholders.
What is the beta indicator for Spero Therapeutics?
Spero Therapeutics (SPRO) has a beta rating of 0.62. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Spero Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.